NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give NRx Pharmaceuticals a “Moderate Buy” consensus: four rate the stock a buy, one says hold and one says sell. The average 12-month price target is $34.50, though recent targets and ratings have been mixed.
• NRXP was trading at $3.27, down 2.1%, with a market capitalization of approximately $118.5 million. The stock has traded between $1.62 and $5.05 over the past year.
• The company reported a quarterly loss of $0.18 per share, missing the $0.09 consensus estimate, while revenue of $1.10 million also fell short of analysts’ $1.33 million forecast. Institutional investors own 4.27% of the stock.

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $34.50.

Several research analysts recently issued reports on NRXP shares. BTIG Research reduced their target price on shares of NRx Pharmaceuticals to $10.00 and set a "buy" rating for the company in a report on Friday, August 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. HC Wainwright reissued a "buy" rating on shares of NRx Pharmaceuticals in a report on Monday. Wall Street Zen lowered NRx Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, Ascendiant Capital Markets raised their price objective on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a "buy" rating in a research note on Monday, April 27th.

Institutional Trading of NRx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Ethos Financial Group LLC increased its holdings in NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company's stock valued at $34,000 after buying an additional 4,000 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth about $107,000. Two Sigma Investments LP boosted its stake in shares of NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company's stock worth $173,000 after acquiring an additional 20,880 shares in the last quarter. State Street Corp grew its position in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company's stock valued at $236,000 after acquiring an additional 10,700 shares during the period. Finally, Bleakley Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at about $318,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Trading Down 2.1%

NRXP opened at $3.27 on Friday. NRx Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $5.05. The firm has a market capitalization of $118.47 million, a PE ratio of -3.00 and a beta of 2.18. The firm has a 50 day moving average of $3.80 and a two-hundred day moving average of $2.95.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.09). The business had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.33 million. As a group, analysts predict that NRx Pharmaceuticals will post -0.3 EPS for the current fiscal year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company's research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx's pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source